A multifunctional nanotheranostic system for imaging guided chemo-and photothermal synergistic therapy for cancer has been developed,in which the aggregation-induced emission(AIE)luminogen functionalised mesoporous si...A multifunctional nanotheranostic system for imaging guided chemo-and photothermal synergistic therapy for cancer has been developed,in which the aggregation-induced emission(AIE)luminogen functionalised mesoporous silica nanoparticles(MSNs)act as anticancer drug carriers and biological imaging agents,and CuS nanoparticles attached to the silica nanosphere surface as the photothermal agent.The obtained nanocomposites(denoted as CFMSNs)exhibit a blue emission and have good biocompatibility,and can be used as an effective luminescent bioprobe for intracellular imaging.Furthermore,the nanoplatform can induce obvious thermal effects after the exposure to an 808 nm laser and serve as an effective pH-dependent NIR-responsive release system.More importantly,the combination of chemotherapy and photothermal therapy shows a better therapeutic effect than the individual therapies,thus demonstrating a synergistic action towards anticancer therapy.展开更多
Extracellular vesicles(EVs)are lipid bilayer-enclosed vesicles released by cells.EVs encapsulate proteins and nucleic acids of their parental cell and efficiently deliver the cargo to recipient cells.These vesicles ac...Extracellular vesicles(EVs)are lipid bilayer-enclosed vesicles released by cells.EVs encapsulate proteins and nucleic acids of their parental cell and efficiently deliver the cargo to recipient cells.These vesicles act as mediators of intercellular communication and thus play a crucial role in various physiological and pathological processes.Moreover,EVs hold promise for clinical use.They have been explored as drug delivery vehicles,therapeutic agents,and targets for disease diagnosis.In the landscape of cancer research,while strides have been made in EV-focused cancer physiopathology,liquid biopsy,and drug delivery,the exploration of EVs as immunotherapeutic agents may not have seen substantial progress to date.Despite promising findings reported in cell and animal studies,the clinical translation of EV-based cancer immunotherapeutics encounters challenges.Here,we review the existing strategies used in EV-based cancer immunotherapy,aiming to propel the development of this emerging yet crucial field.展开更多
基金supported by the State Basic Research Project of China(Grant No.2014CB931802)the National Natural Science Foundation of China(Grant No.21320102001 and 21621001).
文摘A multifunctional nanotheranostic system for imaging guided chemo-and photothermal synergistic therapy for cancer has been developed,in which the aggregation-induced emission(AIE)luminogen functionalised mesoporous silica nanoparticles(MSNs)act as anticancer drug carriers and biological imaging agents,and CuS nanoparticles attached to the silica nanosphere surface as the photothermal agent.The obtained nanocomposites(denoted as CFMSNs)exhibit a blue emission and have good biocompatibility,and can be used as an effective luminescent bioprobe for intracellular imaging.Furthermore,the nanoplatform can induce obvious thermal effects after the exposure to an 808 nm laser and serve as an effective pH-dependent NIR-responsive release system.More importantly,the combination of chemotherapy and photothermal therapy shows a better therapeutic effect than the individual therapies,thus demonstrating a synergistic action towards anticancer therapy.
基金supported by the National Cancer Institute(grants R01CA230339 and R37CA255948).
文摘Extracellular vesicles(EVs)are lipid bilayer-enclosed vesicles released by cells.EVs encapsulate proteins and nucleic acids of their parental cell and efficiently deliver the cargo to recipient cells.These vesicles act as mediators of intercellular communication and thus play a crucial role in various physiological and pathological processes.Moreover,EVs hold promise for clinical use.They have been explored as drug delivery vehicles,therapeutic agents,and targets for disease diagnosis.In the landscape of cancer research,while strides have been made in EV-focused cancer physiopathology,liquid biopsy,and drug delivery,the exploration of EVs as immunotherapeutic agents may not have seen substantial progress to date.Despite promising findings reported in cell and animal studies,the clinical translation of EV-based cancer immunotherapeutics encounters challenges.Here,we review the existing strategies used in EV-based cancer immunotherapy,aiming to propel the development of this emerging yet crucial field.
